Cargando…

Evaluation of the impact of dutasteride/tamsulosin combination therapy on libido in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH): A post hoc analysis of a prospective randomised placebo‐controlled study

AIMS: Five‐α reductase inhibitor (5ARI) therapy has been associated with sexual dysfunction in some patients. This study assessed the impact of a fixed‐dose combination of the 5ARI dutasteride 0.5 mg and the α(1)‐adrenoceptor antagonist tamsulosin 0.4 mg (DUT‐TAM FDC) on Men's Sexual Health Que...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rosen, Raymond C., Roehrborn, Claus G., Manyak, Michael J., Palacios‐Moreno, Juan Manuel, Wilson, Timothy H., Lulic, Zrinka, Giuliano, Francois
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Urology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767409/ https://www.ncbi.nlm.nih.gov/pubmed/30317693 http://dx.doi.org/10.1111/ijcp.13282

Ejemplares similares

Men’s Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo‐controlled study
por: Roehrborn, Claus G., et al.
Publicado: (2020)

Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression
por: D’Agate, Salvatore, et al.
Publicado: (2020)

Persistence and adherence to dutasteride/tamsulosin fixed-dose versus free-combination alpha blocker/5ARI therapy in patients with benign prostate hyperplasia in Germany
por: Eisen, Christoph, et al.
Publicado: (2020)

Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED
por: Sebastianelli, A., et al.
Publicado: (2020)

The Effect of Tamsulosin, Dutasteride Monotherapy and Tamsulosin-Dutasteride Combination on Prostate Smooth Muscle Contractility in BPH Model Wistar Strain Rattus Novergicus
por: Daryanto, Besut, et al.
Publicado: (2023)

Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH
por: D’Agate, Salvatore, et al.
Publicado: (2019)

Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil
por: Park, Hyun Jun, et al.
Publicado: (2013)

Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia
por: Zhou, Zhongbao, et al.
Publicado: (2019)

Free combination of dutasteride plus tamsulosin for the treatment of benign prostatic hyperplasia in South Korea: analysis of drug utilization and adverse events using the National Health Insurance Review and Assessment Service database
por: Lulic, Zrinka, et al.
Publicado: (2021)

Non-Invasive Predictors of Response to Tamsulosin for Benign Prostatic Obstruction
por: Shoaib, Mohammad, et al.
Publicado: (2021)

Relationship among diet habit and lower urinary tract symptoms and sexual function in outpatient-based males with LUTS/BPH: a multiregional and cross-sectional study in China
por: Chen, Yuke, et al.
Publicado: (2016)

Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH – a double-blind randomized trial
por: Manohar, Chikka Moga Siddaiah, et al.
Publicado: (2017)

Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients
por: Alcaraz, Antonio, et al.
Publicado: (2021)

Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability
por: Barkin, Jack
Publicado: (2011)

Effect of combination treatment on patient-related outcome measures in benign prostatic hyperplasia: clinical utility of dutasteride and tamsulosin
por: Djavan, Bob, et al.
Publicado: (2011)

Understanding patient and physician perceptions of benign prostatic hyperplasia in Asia Pacific, Latin America and the Commonwealth of Independent States: the Prostate Research on Behaviour and Education (PROBE) II survey
por: Ertel, Phillip, et al.
Publicado: (2016)

Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH
por: Roehrborn, C G, et al.
Publicado: (2011)

Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride
por: Kuiper, Josephina G., et al.
Publicado: (2016)

A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model
por: Udeh, Emeka I., et al.
Publicado: (2016)

Dutasteride plus Tamsulosin fixed-dose combination first-line therapy versus Tamsulosin Monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting
por: Geitona, Maria, et al.
Publicado: (2014)

PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH
por: Gacci, M., et al.
Publicado: (2013)

Rezum Therapy for Benign Prostatic Hyperplasia: Dubai’s Initial Experience
por: Rowaiee, Rashed, et al.
Publicado: (2021)

A Scoping Review of the Management of Benign Prostate Hyperplasia in Africa
por: Zubair, Abdulahi, et al.
Publicado: (2022)

Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study
por: Roehrborn, Claus G., et al.
Publicado: (2016)

Prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) in China: results from the China Health and Retirement Longitudinal Study
por: Zhang, Weiyu, et al.
Publicado: (2019)

The EXPANDER-1 trial: introduction of the novel Urocross™ Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)
por: Woo, Henry H., et al.
Publicado: (2022)

Clinical Benefit of Tamsulosin and the Hexanic Extract of Serenoa Repens, in Combination or as Monotherapy, in Patients with Moderate/Severe LUTS-BPH: A Subset Analysis of the QUALIPROST Study
por: Alcaraz, Antonio, et al.
Publicado: (2020)

Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate
por: Miller, J, et al.
Publicado: (2009)

Effects of dutasteride and tamsulosin on penile morphology in a rodent model
por: Da Silva, Marcello H. A., et al.
Publicado: (2023)

Current consensus and controversies on male LUTS/BPH (part one)
por: Foo, Keong Tatt
Publicado: (2017)

Current consensus and controversies on male LUTS/BPH (part two)
por: Foo, Keong Tatt
Publicado: (2018)

Moving beyond BPH – A contemporary update on male LUTS
por: Chapple, Christopher R.
Publicado: (2019)

Patient’s adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?
por: Cindolo, Luca, et al.
Publicado: (2015)

A Comparison Between Silodosin and Tamsulosin for Medical Expulsive Therapy of Distal Ureteric Calculus
por: Abdullah, Atif, et al.
Publicado: (2023)

Minimally Invasive Treatment in Benign Prostatic Hyperplasia (BPH)
por: Sciacqua, L. V., et al.
Publicado: (2023)

Economic Evaluation for Benign Prostatic Hyperplasia in Iran: Surgical Treatment or Dutasteride
por: Khedmati, Jamaleddin, et al.
Publicado: (2021)

Making shared decisions with older men selecting treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH): a pilot randomized trial
por: Ngu, Haidee, et al.
Publicado: (2022)

Metformin use and long-term risk of benign prostatic hyperplasia: a population-based cohort study
por: Nørgaard, Mette, et al.
Publicado: (2020)

Long-Term Risk of Surgery Following First Diagnosis of Benign Prostatic Hyperplasia in Middle-Aged Men
por: Rojanasarot, Sirikan, et al.
Publicado: (2022)

Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study
por: Toren, Paul, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_pnnd3t2u91gmla43vm03ocacmd